Plain-English translation of NCT05096390 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two medications—axitinib (a drug that slows tumor blood vessel growth) and pembrolizumab (an immunotherapy that helps your immune system fight cancer)—works better than axitinib alone for treating advanced papillary renal cell carcinoma. You would be randomly assigned to receive either the combination or axitinib by itself, with doctors tracking how well the treatment controls your cancer over time.
Papillary renal cell carcinoma is a specific subtype of kidney cancer that hasn't had a standard proven treatment plan like other kidney cancers do. Early research suggests that combining this medication with immunotherapy might help more patients respond to treatment, which is why researchers want to test this approach in a larger group.
You will take the study medication by mouth twice daily, either axitinib alone or axitinib combined with pembrolizumab (which is given as an intravenous infusion every 3 weeks). You'll attend regular clinic visits for blood tests, imaging scans to measure your tumor, and check-ins to monitor for side effects. Your doctors may adjust your medication dose based on how well you tolerate it. The trial will follow your progress for an extended period to see how long the treatment helps control your cancer.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France